NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients
NexImmune will soon initiate a Phase 1/2 trial evaluating its cell therapy NEXI-002 in people with multiple myeloma who failed three or…
Myeloma
IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma
In partnership with Medscape Oncology, the International Myeloma Foundation (IMF) is offering a professional education series on continuous treatment in multiple…
First Mainland China Patient Dosed in Pivotal Phase 2 Trial Testing MOR202 in Multiple Myeloma
I-Mab Biopharma has dosed the first patient in mainland China in its ongoing, pivotal Phase 2 trial assessing MorphoSys‘s investigational antibody therapy…
Pivotal DREAMM-2 Trial Supports Belantamab Mafodotin’s Use for Heavily-treated Multiple Myeloma
Treatment with belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, resulted in clinically meaningful responses in about one-third of hard-to-treat multiple…
Myeloma Patients in Phase 1 Trial Show High Response Rates with REGN5458 Treatment
Treatment with Regeneron Pharmaceuticals‘ investigational therapy REGN5458 was well tolerated and significantly lowered the tumor burden in more than…
PNK-007 Treatment After Stem Cell Transplant Leads to Good Response Rates in Multiple Myeloma Patients, Early Trial Data Show
A single infusion of Celularity‘s PNK-007 — an investigational cell therapy derived from placental stem cells — is safe and leads to good response…
Analysis Group Announces Collaboration to Improve Blood Disease Research and Treatment in China
Analysis Group is collaborating with China’s Institute of Hematology & Blood Diseases Hospital (IHBDH) to develop the country’s first blood disorders research platform…
Top 10 Multiple Myeloma Stories of 2019
Myeloma Research News brought you daily coverage of important findings, treatment developments, clinical trials, and other events related to multiple myeloma…
Switching Chemo Types in Initial Combo May Help Myeloma Patients with Poor Response, Study Says
For people with multiple myeloma who don’t respond well to an initial type of therapy, quickly switching to another type may improve clinical outcomes,…
CHMP Recommends EU Approval of Darzalex Combo as First-line Treatment for Transplant-eligible Myeloma Patients
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Darzalex (daratumumab), in combination with standard pre-transplant therapy, for the treatment of…
